MedZora Article

Fecal calprotectin has become a useful tool for people living with inflammatory bowel disease (IBD). It offers a window into gut inflammation without the need for an invasive procedure, and it can give clues about disease activity before symptoms appear. Dr. Sameer Idris, a gastroenterologist practicing in the UAE, often explains how a simple stool test can help guide treatment decisions and reduce the number of unnecessary colonoscopies. Why monitoring stool matters

IBD, which includes Crohn's disease and ulcerative colitis, follows a pattern of flare‑ups and remission. Relying only on how a patient feels can miss inflammation that is already building up. Studies suggest that stool‑based markers can detect microscopic inflammation even when patients report no pain or diarrhea. However, test results must be interpreted alongside clinical assessment, as other factors such as infections or certain medications can raise the marker level. What fecal calprotectin tells us

Calprotectin is a protein released by white blood cells when they encounter intestinal inflammation. Laboratory analysis measures the amount of this protein in a small stool sample. Research indicates that higher calprotectin concentrations correlate with active inflammation in the colon or small intestine. In many patients, a rise in the marker precedes a clinical flare by several weeks, giving the care team an opportunity to adjust therapy early. Yet, the test is not perfectly specific; non‑IBD conditions like gastrointestinal infections or the use of non‑steroidal anti‑inflammatory drugs (NSAIDs) can also raise levels, and low levels do not guarantee that disease activity is absent. How the test is done

The procedure is straightforward. Patients collect a small amount of stool using a kit provided by the clinic or pharmacy. The sample is placed into a container with a stabilising buffer and returned to the laboratory, usually within 24 hours. The lab uses an immuno‑assay to quantify calprotectin, reporting the result in micrograms per gram of stool. Normal ranges vary between laboratories, but many use a cut‑off of around 50 µg/g to distinguish low from potentially active disease. It is common to repeat the test after a few weeks if an initial result is borderline or if symptoms change. When we use it in practice

Dr. Idris typically orders fecal calprotectin:

• At diagnosis, to help differentiate IBD from irritable bowel syndrome (IBS), where inflammation is usually absent.
• During routine follow‑up, especially when a patient feels well but the clinician wants to confirm remission.
• Before planning a colonoscopy, to decide whether the procedure is likely to show active disease or can be safely delayed.
• When there is a suspicion of a flare, to guide medication adjustments before symptoms worsen.

The decision to act on a calprotectin result is individualized. A modest increase may lead to closer monitoring, while a substantial rise could prompt a discussion about stepping up medication. The approach also considers the patient's history, current medication, and any concurrent health issues. Practical steps for patients

1. Collect the sample correctly - Follow the kit instructions, avoid contaminating the stool with urine or toilet water, and seal the container tightly. 2. Store and transport promptly - Keep the sample at room temperature if the lab will receive it within a day, or refrigerate if there will be a delay. 3. Inform your doctor about recent infections or NSAID use - This information helps the clinician interpret the result accurately. 4. Ask what the result means for your treatment - Understanding whether a change in medication is needed or if the current plan can continue reduces uncertainty. 5. Keep a symptom diary - Recording bowel habits, pain, and any medication changes alongside test dates can make future discussions more productive. Key takeaways

• Fecal calprotectin measures a protein linked to gut inflammation and can signal IBD activity before symptoms appear.
• The test is non‑invasive, quick, and can help decide if a colonoscopy is needed.
• Results must be viewed with other clinical information, as infections or certain drugs can also raise levels.
• Regular monitoring can allow timely medication adjustments, potentially reducing flare severity.
• Proper sample collection and clear communication with your gastroenterology team improve the usefulness of the test.

This article provides general information only and does not substitute personal medical advice. Please discuss any concerns or test results with your own clinician.

This article was written by Dr. Sameer Idris, a Gastroenterology (IBD and gut health) specialist. For more evidence-based medical content from Dr. Sameer Idris, visit the MedZora Blog.